# We Have No Lab. We Just Read Everyone Else's. > About Magnifico Lab Peptides — Reporting From Inside the Research Record — Magnifico Lab Peptides is an independent editorial desk that reports on the published research literature for four peptides. Not a lab, not a clinic, not a vendor — and here is exactly how we read a study. **INSIDE THE LAB / ABOUT** How Magnifico Lab Peptides works, what the name actually means, and the editorial rules that govern every page on this site. ## What this site is Magnifico Lab Peptides is a reporting desk that reads the published research literature on a small set of peptides and translates it into plain, accurate language. The name is a nod to the site's method, not a claim about a facility — **we do not run a laboratory, we do not conduct experiments, and we do not manufacture, stock or sell any compound.** Every finding on this site traces back to a specific published study: an in vitro assay, an animal model, or a human trial. We name which one, every time, because the difference between a mouse result and a human result is not a footnote — it's the whole story. ## How we read a study Our method borrows something from science journalism and something from peer review. For every claim, we ask three questions before it goes on the page: What was actually tested — a cell line, an animal, or a person? What was the study design — an open-label pilot or a randomized, controlled trial? And what did the result actually show, including when it *didn't* clear the bar the researchers set for it? Ipamorelin's one human trial is a good example — the numbers moved in the hoped-for direction, but not by a statistically significant margin, and we report that plainly rather than rounding it up to a success [3]. That third question — reporting negative and null findings honestly — is where a lot of secondary peptide coverage online quietly fails, and it's the discipline this site tries hardest to hold. ## What this site does not do This site does not recommend a dose for any person, does not offer medical advice, and does not tell anyone what to buy or where. It does not evaluate research-chemical suppliers, verify product purity, or facilitate a purchase of any kind. Where community reports of real-world experience are included, they are always labeled as anecdotal — never presented as clinical fact, and never paired with a specific dose. Where a compound's evidence is thin or entirely preclinical, as with KPV and MOTS-c, this site says so directly rather than papering over the gap with confident-sounding language borrowed from a more advanced compound. ## Sourcing and corrections Every citation on this site links to a peer-reviewed journal article, a clinical-reference source, or a primary trial registration, listed in full on the [references page](/references). We re-verify identifiers like DOIs and PMIDs against their primary sources rather than trusting secondary web aggregators — a habit that matters more than it sounds, since misattributed identifiers are a documented, recurring problem in online peptide coverage. If a study we've cited is corrected, retracted, or superseded, our aim is to update the relevant page rather than let outdated claims sit indefinitely. ## Who this is for This site is written for the reader who wants to understand what the research literature actually says about ipamorelin, KPV, MOTS-c and tirzepatide — not a marketing summary of it. If that describes you, start with [what's inside the lab](/), or jump straight to a [side-by-side comparison](/compare) of all four compounds. --- Magnifico Lab Peptides is a reporting desk that reads other researchers' bench work for a living — we hold no lab, run no assays, and stock nothing, so every claim you find here traces back to a published study, never to our own beaker.